The drug repurposing service providers market is projected to grow at an annualized rate of 14.7%, till 2030
Roots Analysis has done a detailedstudy on DrugRepurposing Service Providers Market, 2020-2030.”
covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.
To order this 250+ page report, which features 100+ figuresand 140+ tables, please visit this https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html
Key Market Insights
§ More than 60 industryplayers across the world are presently engaged in providing services for therepurposing of therapeutics
§ The dataset featuresa variety of CRO, big data / analytics and technology-based service providers,offering repurposing services by using different type of repurposing approachesand drug molecules
§ Over 1,700 discontinued clinical studies of therapeutics canbe considered as potential candidates for repurposing
§ In the pursuit ofobtaining an edge within this emerging and highly competitive market landscape,service providers are actively exploring the therapeutic potential of theexisting approved drugs by providing the necessary support to drug developersin identifying / predicting prospective drug candidates for repurposing.
§ Over time, recent initiatives have been undertaken by big pharma playersacross the world for the discovery and development of repurposed drugs
§ Several organizationshave extended financial support to aid research efforts in this domain; thecurrent focus is on investigation of novel immune checkpoint pathways / targetsfor coronavirus disease
§ The growing interest in this field is also reflected by the 10+partnerships have been signed in the last three years, involving bothinternational and indigenous stakeholders
§ The future market,based on the revenue generation potential of repurposed drugs, is anticipatedto be distributed across different disease areas and key geographical regions
§ In the long term, theopportunity is likely to be segmented across type of repurposing approaches,purpose of repurposing and type of drug molecule
For more information, please visit https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview ofDrug Repurposing
3.2.1 History ofDrug Repurposing
3.2.2 Strategiesfor Drug Repurposing
3.3. Repurposingversus the Traditional Drug Discovery
3.4. Benefitsand Challenges Associated with Drug Repurposing
3.5. DrugRepurposing Service Providers
4. MARKETLANDSCAPE
4.1. ChapterOverview
4.2. DrugRepurposing Service Provider: Overall Market Landscape of Contract ResearchOrganizations (CROs)
4.2.1. Analysis byYear of Establishment
4.2.2. Analysis byCompany Size
4.2.3. Analysis byLocation of Headquarters
4.2.4. Analysis byCompany Size and Location of Headquarters
4.2.5. Analysis byType of Drug Molecule
4.2.6. Analysis byStatus of Drug
4.2.7. Analysis byRepurposing Approach
4.2.8. Analysis byServices Offered
4.3. DrugRepurposing Service Provider: Overall Market Landscape of Big Data / AnalyticsService Providers
4.3.1. Analysis byYear of Establishment
4.3.2. Analysis byCompany Size
4.3.3. Analysis byLocation of Headquarters
4.3.4. Analysis byCompany Size and Location of Headquarters
4.3.5. Analysis byTechnology Specifications
4.3.6. Analysis byType of Drug Molecule
4.3.7. Analysis byStatus of Drug
4.3.8. Analysis byRepurposing Approach
4.3.9. Analysis byServices Offered
4.4. Drug RepurposingService Provider: Overall Market Landscape of Technology Providers
4.4.1. Analysis byYear of Establishment
4.4.2. Analysis byCompany Size
4.4.3. Analysis byLocation of Headquarters
4.4.4. Analysis byCompany Size and Location of Headquarters
4.4.5. Analysis byTechnology Specifications
4.4.6. Analysis byType of Drug Molecule
4.4.7. Analysis byStatus of Drug
4.4.8. Analysis byRepurposing Approach
4.2.9. Analysis byServices Offered
5. ROLE OF NON-PROFIT / ACADEMIC ORGANIZATIONS
5.1. ChapterOverview
5.2. DrugRepurposing Service Providers: List of Non-Profit Organizations
5.3. StakeholderProfiles
5.3.1. Cures WithinReach
5.3.2. GlobalCures
5.3.3. AnticancerFund
5.3.4. NationalCenter for Advancing Translational Sciences
5.4. DrugRepurposing Service Providers: List of Academic Organizations
6. COMPANY PROFILES
6.1. ChapterOverview
6.2. CompanyProfiles for CROs
6.2.1. AuxiliisPharma
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Future Outlook
6.2.2. ChemBioDiscovery Solutions
6. 2.2.1. Company Overview
6. 2.2.2. Service Portfolio
6. 2.2.3. Future Outlook
6.2.3. GVK BIO
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Service Portfolio
6.2.3.4. Future Outlook
6.2.4. Iris Pharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Future Outlook
6.2.5. Physiogenex
6.2.5.1. Company Overview
6.2.5.2. ServicePortfolio
6.2.5.3. Future Outlook
6.3. CompanyProfiles for Big Data / Analytics Service Providers
6.3.1. Excelra
6.3.1.1. Company Overview
6.3.1.2. TechnologyOverview
6.3.1.3. Service Portfolio
6.3.1.4. Future Outlook
6.3.2. Smart Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Service Portfolio
6.3.2.4. Future Outlook
6.4. CompanyProfiles for Technology Providers
6.4.1. LanternPharma
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Service Portfolio
6.4.1.4. Future Outlook
6.4.2. Panxome
6.4.2.1. Company Overview
6.4.2.2. Technology Overview
6.4.2.3. Service Portfolio
6.4.2.4. Future Outlook
6.4.3. Pharmacelera
6.4.3.1. Company Overview
6.4.3.2. Technology Overview
6.4.3.3. Service Portfolio
6.4.3.4. Future Outlook
6.4.4. Socium
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Future Outlook
6.4.5. SOM Biotech
6.4.5.1. Company Overview
6.4.5.2. Technology Overview
6.4.5.3. Service Portfolio
6.4.5.4. Future Outlook
7. PARTNERSHIPS
7.1. ChapterOverview
7.2. PartnershipModels
7.3. DrugRepurposing Service Providers: List of Partnerships
7.3.1. Analysis byYear of Partnership
7.3.2. Analysis byType of Partnership
7.3.3. Analysis byYear and Type of Partnership
7.3.4. Analysis byType of Technology / Platform Used
7.3.5. Analysis byTherapeutic Area
7.3.6. GeographicalAnalysis
7.3.6.1. Continent-wise Distribution
7.3.6.2. Country-wise Distribution
8. BIG PHARMA INITIATIVES
8.1. ChapterOverview
8.2. List of DrugRepurposing Initiatives of Big Pharma Players
8.2.1. Analysis byNumber of Initiatives
8.2.2. Analysis byYear of Initiative
8.2.3. Analysis byType of Initiative
8.2.4. Analysis byTherapeutic Area
8.2.5. Analysis byType of Drug Molecule
8.2.6. Big PharmaActivity: Analysis by Year of Initiative and Company
8.2.7. Big PharmaActivity: Analysis by Type of Drug Molecule and Company
8.3. CompetitiveBenchmarking of Big Pharma Players
8.3.1. Big PharmaInvestment Summary
8.4. InitiativesUndertaken by Leading Players
8.4.1. InitiativesUndertaken by AbbVie
8.4.1.1. In-House Initiatives
8.4.2. InitiativesUndertaken by Astellas Pharma
8.4.2.1. Initiatives in Collaboration with OtherStakeholders
8.4.2.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.3. InitiativesUndertaken By AstraZeneca
8.4.3.1. In-House Initiatives
8.4.3.2. Initiatives in Collaboration with OtherStakeholders
8.4.4. InitiativesUndertaken by Bayer
8.4.4.1. Initiatives in Collaboration with OtherStakeholders
8.4.5. InitiativesUndertaken by Boehringer Ingelheim
8.4.5.1. Initiatives in Collaboration with OtherStakeholders
8.4.5.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.6. InitiativesUndertaken by Eli Lilly
8.4.6.1. Initiatives in Collaboration with OtherStakeholders
8.4.6.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.7. Initiatives Undertaken by Gilead Sciences
8.4.7.1. Recent Regulatory Approvals of Repurposed Drugs
8.4.8. InitiativesUndertaken by GSK
8.4.8.1. In-House Initiatives
8.4.8.2. Initiatives in Collaboration with OtherStakeholders
8.4.9. InitiativesUndertaken by Novartis
8.4.9.1. In-House Initiatives
8.4.9.2. Initiatives in Collaboration with OtherStakeholders
8.4.9.3. Recent Regulatory Approvals of Repurposed Drugs
8.4.10. InitiativesUndertaken by Roche
8.4.10.1. In-House Initiatives
8.4.10.2. Initiatives in Collaboration with OtherStakeholders
8.4.11. InitiativesUndertaken by Sanofi
8.4.11.1. In-House Initiatives
8.4.11.2. Recent Regulatory Approvals of Repurposed Drugs
8.5. Other BigPharma Players
8.5.1. InitiativesUndertaken by Pfizer
8.5.1.1. Initiatives in Collaboration with OtherStakeholders
9. CASE STUDY: DISCONTINUED DRUGDEVELOPMENT PROGRAMS
9.1. ChapterOverview
9.2. Scope andMethodology
9.3. DrugRepurposing: Discontinued Clinical Trials
9.3.1. Analysisby Trial Status
9.3.2. Analysisby Trial Phase
9.3.3. Analysisby Cause of Discontinuation of Clinical Research
9.3.4. Analysisby Therapeutic Area
9.3.5. Analysisby Trial Status and Location of Trial Site
9.3.6. Analysisby Phase Distribution versus Cause of Discontinuation of Clinical Research
9.3.7. Analysis byTrial Phase and Target Therapeutic Area
9.3.8. Analysis byCause of Discontinuation of Clinical Research and Target Therapeutic Area
9.4. DiscontinuedClinical Trials Analysis: Key Therapeutic Area
9.4.1. DiscontinuedClinical Trials: Oncology Disorders
9.4.1.1. Analysis by Trial Status
9.4.1.2. Analysis by Trial Phase
9.4.1.3. Analysis by Cause of Discontinuation of ClinicalResearch
9.4.1.4. Analysis by Trial Status and Location of TrialSite
9.4.2. DiscontinuedClinical Trials Analysis: CNS Disorders
9.4.2.1. Analysis by Trial Status
9.4.2.2. Analysis by Trial Phase
9.4.2.3. Analysis by Cause of Discontinuation of ClinicalResearch
9.4.2.4. Analysis by Trial Status and Location of TrialSite
9.4.3. DiscontinuedClinical Trials Analysis: Metabolic Disorders
9.4.3.1. Analysis by Trial Status
9.4.3.2. Analysis by Trial Phase
9.4.3.3. Analysis by Cause of Discontinuation of ClinicalResearch
9.4.3.4. Analysis by Trial Status and Location of TrialSite
9.4.4. DiscontinuedClinical Trials Analysis: Infectious Disorders
9.4.4.1. Analysis by Trial Status
9.4.4.2. Analysis by Trial Phase
9.4.4.3. Analysis by Cause of Discontinuation of ClinicalResearch
9.4.4.4. Analysis by Trial Status and Location of TrialSite
9.4.5. DiscontinuedClinical Trials Analysis: Autoimmune Disorders
9.4.5.1. Analysis by Trial Status
9.4.5.2. Analysis by Trial Phase
9.4.5.3. Analysis by Cause of Discontinuation of ClinicalResearch
9.4.5.4. Analysis by Trial Status and Location of TrialSite
9.5. List of Potential Drug Candidates
10. COST SAVING ANALYSIS
10.1. ChapterOverview
10.2. Cost SavingPotential
10.2.1. Opinion ofIndustry Experts
10.3. KeyTherapeutic Areas
10.3.1. OncologyDisorders
10.3.2. NeurologicalDisorders
10.3.3. MetabolicDisorders
10.3.4. InfectiousDiseases
10.3.5. RareDisorders
10.4. ConcludingRemarks
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. ChapterOverview
11.2. KeyAssumptions
11.3. ForecastMethodology
11.4. OverallDrug Repurposing Services Market, 2020-2030
11.4.1. DrugRepurposing Services Market: Distribution by Type of Drug Molecule, 2020, 2025and 2030
11.4.1.1. Drug Repurposing Services Market for SmallMolecules, 2020-2030
11.4.1.2. Drug Repurposing Services Market for Biologics,2020-2030
11.4.2. DrugRepurposing Services Market: Distribution by Type of Repurposing Approach,2020-2030
11.4.2.1. Drug Repurposing Services Market usingDisease-Centric Approach, 2020-2030
11.4.2.2. Drug Repurposing Services Market usingTarget-Centric Approach, 2020-2030
11.4.2.3. Drug Repurposing Services Market usingDrug-Centric Approach, 2020-2030
11.4.3. DrugRepurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and2030
11.4.3.1. Drug Repurposing Services Market for DifferentTherapeutic Area, 2020-2030
11.4.3.2. Drug Repurposing Services Market for SameTherapeutic Area, 2020-2030
11.4.4. DrugRepurposing Services Market: Distribution by Geography, 2020-2030
11.4.4.1. Drug Repurposing Services Market in NorthAmerica, 2020-2030
11.4.4.2. Drug Repurposing Services Market in Europe,2020-2030
11.4.4.3. Drug Repurposing Services Market in Asia Pacificand RoW, 2020-2030
12. COVID-19 IMPACT ON DRUG REPURPOSINGSERVICE PROVIDERS MARKET
12.1. ChapterOverview
12.2. CurrentOpinions and Recuperative Initiatives of Key Players
12.2.1. Excelra
12.2.2. GVK Bio
12.2.3. Biovista
12.2.4. Evotec
12.3. RecuperativeStrategies for Service Providers
12.3.1. Strategiesfor Implementation in the Short / Mid Term
12.3.2. Strategiesfor Implementation in the Long Term
13. RECENTADVANCEMENTS AND TRENDS IN OUTSOURCING OF DRUG REPURPOSING
13.1. ChapterOverview
13.2. Shift fromOne-Time Contracts to Strategic Partnerships
13.3. Adoption ofNew and Innovative Technologies
13.3.1. ArtificialIntelligence
13.3.2. NextGeneration Drug Repurposing Techniques
13.4. Focus on NicheTherapeutic Areas
13.5. Increase inFinancial Inflow and Outsourcing Budgets
14. INTERVIEW TRANSCRIPTS
14.1. ChapterOverview
14.2. Nandu Gattu(Senior Vice President, Excelra)
15. APPENDIX 1: LIST OF POTENTIALDRUG-INDICATION CANDIDATES FOR DRUG REPURPOSING
16. APPENDIX2: TABULATED DATA
17. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
